← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-04-01 11:30:00 | Fda Approves Lilly’s Foundayo™ (orforglipron), The Only Glp-1 Pill For Weight Loss That Can Be Taken Any Time Of Day Without Food Or Water Restrictions Adults taking foundayo lost an average of 27 pounds on the highest dose in the attain-1 clinical trial1 foundayo, lilly’s second fda-approved obesity medicine, will be available via lillydirect ® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-pay indianapolis, april 1, 2026 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the u.s. food and drug administration (fda) approved foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. when used alongside a reduced-calorie diet and increased physical activity, foundayo helps individuals lose excess body weight and keep the weight off. |
| 2026-04-01 09:20:00 | Lexaria To Begin New Human Clinical Study In Glp-1 Contracts signed for human pilot study #7 (glp-1-h26-7) kelowna, bc / access newswire / april 1, 2026 / lexaria bioscience corp. (nasdaq:lexx), (the ’company’ or ’lexaria’), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization (’cro’) to execute and report on its human pilot study #7 (glp-1-h26-7) that will evaluate 2 oral dehydratech-semaglutide (’dht-sema’) compositions against commercially available wegovy® tablets (the ’study’). contracts with the cro have been signed and submissions are currently being prepared to obtain the required ethics approval from an independent review board. |
| 2026-03-30 03:05:00 | Bionxt Advances Semaglutide As First Application Of Broad Glp-1 Odf Platform Strategy Vancouver, bc / access newswire / march 30, 2026 / bionxt solutions inc. (’bionxt’ or the ’company’) (cse:bnxt)(otcqb:bnxtf)(fse:bxt), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide an update on its semaglutide oral thin-film (odf) program and its broader strategy to develop a scalable platform for glp-1 receptor agonists and peptide-based therapeutics. semaglutide as lead candidate for glp-1 platform validation bionxt is currently in early-stage development of its semaglutide odf program, with initial formulation work underway, including preliminary feasibility and exploratory proof-of-concept evaluations. |
| 2026-03-26 16:05:00 | Rani Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results; Provides Corporate Update - announced up to $1.085 billion collaboration with chugai pharmaceutical co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by samsara biocapital with participation from ra capital management, special situations funds, and invus – - announced preclinical data demonstrating successful oral delivery of semaglutide via ranipill® – - announced preclinical data demonstrating the bioequivalence of rt-114, a bispecific glp-1/glp-2 dual agonist (pg-102) delivered orally via the ranipill® capsule, to subcutaneous administration of pg-102 – - initiated phase 1 study of rt-114 ranipill® for the treatment of obesity in collaboration with progen – - conference call today at 4:30 p.m. et / 1:30 p.m. |
| 2026-03-26 12:00:00 | Novo Nordisk’s Fda-approved Glp-1s Now Available With Hims & Hers San francisco--(business wire)--hims & hers health, inc. (nyse: hims) today announced that a broad assortment of novo nordisk’s fda-approved glp-1 medications are available to eligible customers, including the wegovy® pill, which is the only fda-approved glp-1 weight loss pill.1 as a part of a collaboration with novo nordisk, hims & hers is making it simpler for customers to access fda-approved glp-1 medications which are now available at more affordable prices, with more doses and deli. |
| 2026-03-25 16:05:00 |
|
| 2026-03-24 09:15:00 |
|
| 2026-03-18 08:00:00 |
|
| 2026-03-16 07:00:00 |
|
| 2026-03-10 07:30:00 |
|
| 2026-03-10 06:00:00 |
|
| 2026-03-09 07:40:00 |
|
| 2026-03-05 16:07:00 |
|
| 2026-03-03 08:00:00 |
|
| 2026-02-27 16:05:00 |
|
📰 Browse additional press releases for Global Partners!
Sign up for free or log in✅ Download "The Checklist Value Investor — A Smarter Way to Pick Stocks" — totally free!